RESEARCH MONOGRAPH · KDC-MN-363
Erythropoietin (EPO)
Erythropoietin (EPO) is the hormone your kidneys release in response to low oxygen, telling bone marrow to make more red blood cells. Recombinant human EPO (Epogen, Procrit) was approved in 1989 as one of the first commercial recombinant proteins and revolutionized treatment of anemia in chronic kidney disease and chemotherapy. It is also one of the most famous performance-enhancing drugs in endurance sport, with a long history of doping in cycling, cross-country skiing, and distance running. Excessive doses thicken blood enough to cause heart attacks and strokes; the cardiovascular safety signal in dialysis trials led FDA black box warnings in the 2000s. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Glycoprotein hormone (erythropoiesis-stimulating)
The hormone that stimulates red blood cell production; recombinant human EPO is approved for anemia and is widely abused in endurance sports.
Abstract
Erythropoietin (EPO; CAS 11096-26-7; 165-amino-acid glycoprotein with three N-linked and one O-linked glycan chains; molecular weight approximately 30 kDa) is the principal regulatory hormone of erythropoiesis, produced by interstitial fibroblasts in the renal cortex in response to hypoxia. Recombinant human EPO (epoetin alfa, Procrit, Epogen) was approved by the FDA in 1989 as one of the first commercial recombinant proteins. Mechanism: binding to the EPO receptor (homodimer) on erythroid progenitor cells (BFU-E, CFU-E) prevents apoptosis and stimulates proliferation and differentiation, increasing red blood cell production over 1 to 2 weeks. Approved indications: anemia of chronic kidney disease, chemotherapy-induced anemia, anemia in zidovudine-treated HIV, anemia of prematurity, surgical blood conservation. The compound is among the most notorious performance-enhancing substances in endurance sport (cycling, distance running, cross-country skiing) owing to the oxygen-delivery advantage of supranormal hematocrit; the WADA prohibited list and modern biological passport monitoring address this. Plasma half-life is approximately 4 to 13 hours subcutaneous; longer-acting analogs (darbepoetin, methoxy polyethylene glycol-epoetin beta) extend dosing intervals. Used as the canonical erythropoiesis-stimulating agent in research.
Mechanism of action
EPO receptor agonist on erythroid progenitor cells; stimulates red blood cell production over 1 to 2 weeks. Hypoxia-responsive renal hormone.
Reported research dose ranges
Clinical 50 to 300 IU/kg subcutaneous in the published literature; doping use is supratherapeutic.
References
- Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004.
- Lippi G, et al. Recombinant human erythropoietin (rhEPO) and the misuse in sport. Br J Sports Med 2006.
- Kelley LA, et al. EPO use in nephrology: history and impact. Adv Chronic Kidney Dis 2019.
Read the full monograph
The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.